Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 139

Results For "IMI"

4120 News Found

Budget 2024-25: Industry expects push for reforms, R&D and fiscal incentives
News | July 22, 2024

Budget 2024-25: Industry expects push for reforms, R&D and fiscal incentives

Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23


Lupin and Huons Sign agreement for commercialization of cyclosporine ophthalmic nanoemulsion in Mexico
News | July 22, 2024

Lupin and Huons Sign agreement for commercialization of cyclosporine ophthalmic nanoemulsion in Mexico

Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome


Lupin’s partner ForDoz receives USFDA approval for doxorubicin hydrochloride liposome injection
Drug Approval | July 22, 2024

Lupin’s partner ForDoz receives USFDA approval for doxorubicin hydrochloride liposome injection

Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)


Elucid appoints Kelly Huang as CEO
People | July 22, 2024

Elucid appoints Kelly Huang as CEO

Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software


Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India
News | July 19, 2024

Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India

The pooled prevalence of GERD in the Indian population is 15.6 %


Vimta Labs posts Q1 FY25consolidated PAT at Rs. 12.28 Cr
News | July 19, 2024

Vimta Labs posts Q1 FY25consolidated PAT at Rs. 12.28 Cr

Vimta Labs has reported total income of Rs. 82.44 crores during the period ended June 30, 2024


Lupin divests US commercial women's health specialty business to Evofem
News | July 17, 2024

Lupin divests US commercial women's health specialty business to Evofem

Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones


Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India
News | July 17, 2024

Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India

Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders


Merck completes acquisition of EyeBio
News | July 16, 2024

Merck completes acquisition of EyeBio

Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret